Medicare and GLP-1: What's Covered in 2026

For decades, Medicare was statutorily prohibited from covering medications prescribed for weight loss. No matter how obese a beneficiary was, no matter how many comorbidities they carried, Part D could not pay for anti-obesity drugs. In 2026, that wall is finally cracking — though the details matter enormously, and not every Medicare beneficiary will benefit equally.

This guide walks through exactly what has changed, what hasn't, and how to determine whether you can access GLP-1 medications through Medicare this year.

The Two Pathways: Cardiovascular Indication vs. Weight Management

Before diving into the new programs, it's critical to understand that there are now two completely separate pathways for Medicare coverage of GLP-1 medications — and they work very differently.

Pathway 1: Wegovy for Cardiovascular Risk Reduction (Available Now)

In 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight. This is huge for Medicare because it transforms Wegovy from a "weight loss drug" (excluded) into a "cardiovascular drug" (covered under standard Part D rules).

If your doctor prescribes Wegovy using a cardiovascular indication code like I25.10 (atherosclerotic heart disease), standard Medicare Part D coverage applies. That means it goes through your plan's formulary, is subject to normal copays and deductible, and does count toward the Part D out-of-pocket cap — which is $2,100 in 2026 under the Inflation Reduction Act's Part D redesign.

Pathway 2: The Medicare GLP-1 Bridge Program (Starting July 2026)

This is the new one. The CMS BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) creates the first-ever pathway for Medicare to cover GLP-1 medications specifically for obesity and weight management.

The program rolls out in phases:

July 1 – December 31, 2026: The Medicare GLP-1 Bridge demonstration launches nationwide, covering both Wegovy and Zepbound. The monthly copay for beneficiaries is capped at $50. Manufacturers have agreed to a reference price of approximately $245 per month — down from list prices above $900.

January 2027 onward: The BALANCE Model transitions into a voluntary program. Part D plans can choose to opt in and cover GLP-1 medications for obesity. This is a 5-year demonstration running through December 2031 — it is not permanent legislation.

Who Qualifies for the Bridge Program?

Eligibility is phased and based on BMI plus comorbidities. To participate, you must be enrolled in Medicare Part D and meet one of the following criteria:

BMI greater than 27 with prediabetes or established cardiovascular disease.

BMI greater than 30 with uncontrolled hypertension, kidney disease, or heart failure with preserved ejection fraction (HFpEF).

BMI greater than 35 regardless of other conditions.

CMS estimates approximately 10% of Medicare beneficiaries will qualify under these criteria.

Bridge vs. Cardiovascular Coverage: Which Is Better?

If you qualify for both pathways — meaning you have cardiovascular disease and also meet Bridge eligibility — the cardiovascular indication (Pathway 1) is almost certainly better. Here's why:

Under the cardiovascular route, your Wegovy costs count toward your Part D deductible and the $2,100 annual out-of-pocket cap. Once you hit that cap, you pay nothing for the rest of the year. Under the Bridge program, you pay $50 every month all year with no cap relief.

Talk to your prescriber about which indication to use. If you have documented cardiovascular disease, Pathway 1 should be your first choice.

What About Medicare Advantage?

Medicare Advantage (Part C) plans operate under the same Part D drug rules. Some MA plans have begun incorporating obesity management into their supplemental benefits packages, but coverage varies dramatically by plan. If you're on a Medicare Advantage plan, contact your plan directly to ask whether GLP-1 medications are covered under your specific formulary and whether your plan is participating in the Bridge demonstration.

What About Medicaid?

Under the related GENEROUS Model, state Medicaid programs can opt in to cover GLP-1 medications for obesity starting May 2026. However, coverage is optional for states — weight-loss drugs are excluded from the mandatory Medicaid Drug Rebate Program. As of early 2026, only about 13 state Medicaid programs cover GLP-1s for obesity, and several states (including California, New Hampshire, and Pennsylvania) actually eliminated coverage since late 2025.

The Bigger Picture: Is Permanent Coverage Coming?

The Treat and Reduce Obesity Act (TROA) has been reintroduced in Congress with bipartisan support. If passed, it would permanently remove the statutory exclusion of anti-obesity medications from Medicare Part D — no demonstration projects needed. However, as of March 2026, TROA has not passed. The Bridge program and BALANCE Model are executive and administrative actions, not legislation, and could theoretically be modified or ended by a future administration.

Separately, the Inflation Reduction Act's Medicare drug price negotiation program has included GLP-1 medications in Round 2 negotiations. The negotiated price for Ozempic is $274 per month (a 71% reduction from list price), taking effect January 2027.

What to Do Right Now

Step 1: Check your cardiovascular history. If you have documented heart disease, stroke, or peripheral artery disease, ask your doctor about prescribing Wegovy under the cardiovascular indication today. You don't need to wait for any new program.

Step 2: Confirm your Part D plan. Make sure you're enrolled in a Part D plan (or a Medicare Advantage plan with Part D). You'll need active Part D enrollment to participate in the Bridge program when it launches July 1.

Step 3: Calculate your BMI. Use our BMI calculator to determine which eligibility tier you fall into for the Bridge program.

Step 4: Talk to your prescriber before July. Prior authorization for the Bridge program goes through a CMS central processor — not your Part D plan's usual process. Your doctor will need to submit eligibility documentation, so getting that conversation started early is smart.

Step 5: Know your alternatives. If you don't qualify for either pathway, or if the $50 monthly copay is a barrier, there are other options — including patient assistance programs from Novo Nordisk and Eli Lilly that provide medications at no cost to qualifying patients.